» Articles » PMID: 27835603

Microenvironmental Networks Promote Tumor Heterogeneity and Enrich for Metastatic Cancer Stem-like Cells in Luminal-A Breast Tumor Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Nov 12
PMID 27835603
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The roles of the tumor microenvironment (TME) in generating intra-tumoral diversity within each specific breast cancer subtype are far from being fully elucidated. In this study, we exposed Luminal-A breast cancer cells in culture to combined "TME Stimulation", representing three typical arms of the breast TME: hormonal (estrogen), inflammatory (tumor necrosis factor α) and growth-promoting (epidermal growth factor). In addition to enriching the tumor cell population with CD44+/β1+ cells (as we previously published), TME Stimulation selected for CD44+/CD24low/- stem-like cells, that were further enriched by doxorubicin treatment and demonstrated high plasticity in vitro and in vivo. Knock-down experiments revealed that CD44 and Zeb1 regulated CD24 and β1 expression and controlled differently cell spreading and formation of cellular protrusions. TME-enriched CD44+/CD24low/- stem-like cells promoted dissemination to bones and lymph nodes, whereas CD44+/β1+ cells had a low metastatic potential. Mixed co-injections of TME-enriched CD44+/CD24low/- and CD44+/β1+ sub-populations generated metastases populated mostly by CD44+/CD24low/--derived cells. Thus, combined activities of several TME factors select for CD44+/CD24low/- stem-like cells that dictate the metastatic phenotype of Luminal-A breast tumor cells, suggesting that therapeutic modalities targeting the TME could be introduced as a potential strategy of inhibiting the detrimental stem-like sub-population in this disease subtype.

Citing Articles

A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2- Breast Cancer.

Ben-Yaakov H, Meshel T, Pasmanik-Chor M, Korner C, Ben-Baruch A Cancers (Basel). 2023; 15(8).

PMID: 37190183 PMC: 10137120. DOI: 10.3390/cancers15082255.


Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy.

Ben-Baruch A Front Immunol. 2022; 13:903679.

PMID: 35663982 PMC: 9157545. DOI: 10.3389/fimmu.2022.903679.


Cancer Stem Cells: An Ever-Hiding Foe.

Wilczynski J Exp Suppl. 2022; 113:219-251.

PMID: 35165866 DOI: 10.1007/978-3-030-91311-3_8.


Cancer stem cells: a major culprit of intra-tumor heterogeneity.

Naz F, Shi M, Sajid S, Yang Z, Yu C Am J Cancer Res. 2022; 11(12):5782-5811.

PMID: 35018226 PMC: 8727794.


Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy.

Baram T, Rubinstein-Achiasaf L, Ben-Yaakov H, Ben-Baruch A Front Oncol. 2021; 10:614468.

PMID: 33585241 PMC: 7873936. DOI: 10.3389/fonc.2020.614468.


References
1.
Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M . The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007; 26(49):6979-88. PMC: 2899859. DOI: 10.1038/sj.onc.1210508. View

2.
Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

3.
Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M . Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 2006; 97(10):1044-9. PMC: 11160060. DOI: 10.1111/j.1349-7006.2006.00277.x. View

4.
von Minckwitz G, Fontanella C . Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?. Breast. 2013; 22 Suppl 2:S149-51. DOI: 10.1016/j.breast.2013.07.028. View

5.
Abraham B, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H . Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005; 11(3):1154-9. View